Cosmos Health Inc.

Cosmos Health Inc. announced that its wholly owned subsidiary, Cana Laboratories S.A., has acquired international patent application WO2025108566A1 from Cloudpharm P.C. This acquisition is a significant step in expanding the company's nanotechnology investment initiatives and pursuing global patent protection. The underlying technology is set to support the development of next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare products, aligning with Cosmos Health's strategy to grow its intellectual property portfolio and strengthen vertical integration.

Cosmos Health Inc. announced the U.S. launch of Oliv18™, a new USDA and EU organic certified, 100% solvent-free whole olive polyphenol formulation. This product expands its 18 Series nutraceutical platform into the cardiovascular health and antioxidant categories, targeting a combined global market projected to exceed $33 billion by 2035. A single daily dose of Oliv18™ delivers polyphenols equivalent to approximately 11 teaspoons of extra virgin olive oil and meets EFSA's minimum dose for LDL oxidation protection.

Cosmos Health Inc. announced that its proprietary brand, Sky Premium Life, is now available for shipment across all 27 European Union Member States through the e-commerce platform Skroutz. This move significantly expands the brand's international reach, making 96 Sky Premium Life products accessible to consumers across key European markets. CEO Greg Siokas highlighted this expansion as a crucial milestone in their international growth strategy, aiming to enhance brand visibility and drive revenue growth.

Cosmos Health Inc. announced it is exploring the monetization of approximately $20 million in non-core assets to strengthen its balance sheet, fund strategic initiatives, and address its market valuation. These assets include real estate, independently valued at around $15 million, digital assets, and marketable securities. The company stated that the proceeds could be used to fund a significant acquisition or eliminate its debt entirely, while reaffirming its commitment to core healthcare operations.

Cosmos Health Inc. has filed a definitive proxy statement (DEF 14A) announcing its 2026 Annual Meeting of Stockholders scheduled for July 15, 2026. The meeting agenda includes the election of six directors, ratification of the company's independent registered public accounting firm, approval of the 2026 equity incentive plan, and the approval of the designation and issuance of Series B Preferred Stock. The record date for stockholders eligible to vote is May 19, 2026, with 59,956,994 shares of common stock outstanding as of that date. The company encourages stockholders to vote their shares in advance.

Cosmos Health Inc. announced its first entry into the animal health market with the planned launch of a veterinary formulation of its C-Scrub antimicrobial wash brand. The C-Scrub Wash 4% veterinary formulation will initially launch in the United Kingdom, where the human-use brand is already established, with broader international expansion anticipated. This move follows successful independent testing of the product against European veterinary disinfectant standards, demonstrating strong bactericidal and yeasticidal activity. The company aims to capitalize on the rapidly growing global animal health market, which is projected to reach $156.0 billion by 2033.

Cosmos Health Inc. announced its financial guidance for 2026-2029, projecting substantial growth across all key metrics. The company anticipates revenue to increase by 207% to $200.6 million by 2029, with gross profit growing 801% to $71.2 million and gross margins expanding to 35.5%. Cosmos Health expects to achieve net profitability in 2027, reaching $31.0 million by 2029, supported by a strategic shift towards high-margin proprietary products, operational leverage, and global expansion.

Cosmos Health Inc. reported record first-quarter 2026 results, with revenue increasing 30.7% to $17.93 million. The company also significantly reduced total liabilities by $4.51 million and saw stockholders' equity rise by 7.6%. Despite these improvements, the company reported a net loss of $2.81 million and adjusted EBITDA near breakeven, attributed to strategic investments for global growth, including U.S. expansion.

Cosmos Health Inc. reported a net loss of $2.81 million for Q1 2026, significantly wider than the $0.82 million loss in Q1 2025, despite a 30.7% increase in revenue to $17.93 million. The company disclosed substantial doubt about its ability to continue as a going concern due to insufficient revenue to cover operating expenses and debt obligations, coupled with negative operating cash flow of $1.07 million. Management is pursuing strategies including product expansion, new distribution channels, and capital raises through an ATM program and convertible notes to address liquidity challenges.

Cosmos Health Inc. announced its financial results for the fiscal year ended December 31, 2026. The company issued a press release on April 15, 2026, detailing these results. A copy of this press release is included as Exhibit 99.1 to the current report.